Intellia Therapeutics Inc Stock News

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics l

Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. NTLA is on track toward key data and regulatory catalysts. Early clinical data in HAE and

Growth investors are frequently looking for biotech stocks to buy. So what exactly is a biotech stock?

The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate about value investing, you must understand that one o

Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated

Cathie Wood's Ark Innovation fund has identified CRISPR/Cas 9 gene editing as a $2 trillion a year opportunity. Her flagship fund has been buying shares of Intellia Therapeutics this year.

Axsome Therapeutics' pipeline features multiple potentially big winners. CRISPR Therapeutics could be at the beginning of a long-term success story.

Intellia Therapeutics won't be commercializing a drug within a year. It also won't be reporting pivotal clinical trial data.

Cathie Wood has been loading up on Intellia Therapeutics. She's also trimming her holdings of CRISPR Therapeutics, a major competitor.

Alibaba has tremendous growth opportunities in AI. Intellia Therapeutics' gene-editing therapies hold the potential to be big winners.

Intellia Therapeutics is developing gene-editing cures for hereditary diseases. It's succeeding with its early-stage clinical work, but the real tests are yet to come.

Intellia Therapeutics and CRISPR Therapeutics are clinical-stage gene-editing companies. Block is one of the primary fintech companies.

Exchange-traded funds run by Ark Invest bought heaps of growth stocks in the first half of June. Intellia Therapeutics is developing new CRISPR-based therapies that can edit in vivo the genes that lea

Intellia's (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary angioedema.

Intellia (NASDAQ: NTLA ) is trending on social media, and NTLA stock is up over 5% today after the drugmaker reported new, positive results from one of its gene-edited treatments for hereditary angioe